|
PROTOCOL DETAILS |
PROTOCOL TITLE |
DISEASE SITE |
|
|
MT2003-13 Autologous Transplantation for Multiple Myeloma |
|
|
|
MT2006-20: BMT CTN Protocol 0501 - Multi-center, Open Label, Randomized Trial Comparing Single Versus Double Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients with Leukemia and Myelodysplasia |
|
|
|
MT2005-01: Umbilical cord blood transplant with co-infusion of T regulatory cells |
|
|
|
MT2006-01: Phase I Study of Infusion of Umbilical Cord Blood (UCB) Derived CD25+ CD4+ T-Regulatory (Treg) Cells After Non-Myeloablative Cord Blood Transplantation |
|
|
|
MT2005-10: Transplantation of Unrelated Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloblative Preparative Regimen |
|
|
|
MT2005-15: Phase III Rituxan/BEAM vs Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma (CTN 0401) |
|
|
|
MT2003-23: Phase I/II Study of Reduced Intensity Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) Supplemented with Donor Natural Killer (NK) Cell Infusions in High Risk Myeloid Malignancies who are Unsuitable for Fully Myeloablative Transplantation |
|
|
|
Allogeneic natural killer (NK) cells in patients with advanced metastatic breast cancer (MT2005-08) |
Breast |
|
|
Hematopoietic Stem Cell Transplantation in High Risk Patients with Fanconi Anemia MT2002-02 |
|
|
|
MT2003-15 Use of Cyclophosphamide/Fludarabine to Promote in vivo Expansion of Donor Lymphocyte Infusion s(DLI) to Enhance Efficacy after Allogeneic Transplant |
|
|
|
MT2005-18: Transplantation of Umbilical Cord Blood for Myeloid Leukemia Patients Not in CR with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen and UCB NK Cells |
|
|
|
ANHL01P1: A Pilot Study to Determine the Toxicity of Rituximab + COPADM and Rasburicase + COP and LMB/FAB Therapy in Children with Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma |
|
|
|
MT1999-07:Hematopoietic Cell Transplantation for Hurler Syndrome, Maroteaux Lamy Syndrome (MPS VI), and Alpha Mannosidase Deficiency (Mannosidosis) |
|
|
|
131 I-MIBG Escalating Dose Rapid Sequence Double Infusion Followed by Autologous Stem Cell Infusion for Refractory Neuroblastoma |
BRAIN, NOS |
|
|
MT2005-22: Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation from HLA-Compatible Unrelated Donors in Severe Aplastic Anemia (CTN 0301) |
|
|
|
MT2005-21: Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors |
|
|
|
MT2006-03: Defibrotide for the Treatment of Severe Veno-Occlusive DIsease (VOD) in Hematopoietic Stem Cell Transplant Patients: A Historically Controlled Multi-Center Phase 3 Study to Determine Safety and Efficacy |
|
|
|
MT2004-24: Autologous Peripheral Blood Stem Cell Transplant for Patients with Lymphoma |
|
|
|
MT2005-25: Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia |
|
|
|
A Phase I/II Study of Double Unit Umbilical Cord Blood (UCB) Transplantation Utilizing Graft Administration via Intra-Bone Marrow Injection (MT2004-26) |
Hematology:Other |
|
|
MT2004-04: A Multicenter, Prospective Trial to Evaluate the Role of NK Cell Kir Epitope Mismatch on Mortaility and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation |
|
|
|
MT2003-12 A Phase III Randomized, Multicenter Study Comparing G-CSF Mobilized Peripheral Blood Stem Cell with Marrow Transplantation from HLA compatible Unrelated Donors (CTN 0201) |
|
|
|
A Multi-Center Phase III Double-Blind Clinical Trail to Evaluate the Efficacy of Mycophenolate Mofetil (MMF) Added to Prednisone plus Cyclosporine or Tacrolimus for Treatment of Newly Diagnosed Chronic Graft-versus-Host Disease |
BMT; Hematology:Other |
|
|
MT2004-27: Initial System Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (Ontak), and Pentostatin in Combinationwith Corticosteroids (CTN 0302) |
BMT |
